Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Nature cancer·2026
Same author

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Nature medicine·2026
Same author

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.

Nature communications·2026

Related Experiment Video

Updated: Jun 9, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Felipe Galvez-Cancino1, Eileen E Parkes2, David R Withers1

  • 1University of Oxford Oxford United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 8, 2026
PubMed
Summary
This summary is machine-generated.

Next-generation anti-CTLA-4 antibodies enhance tumor activity and reduce toxicity by using improved Fc-mediated function and conditional tumor activation. This approach aims for strong anti-tumor responses without systemic immune issues.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 9, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Area of Science:

  • Immunotherapy
  • Oncology
  • Antibody Engineering

Background:

  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key immune checkpoint inhibitor.
  • Current anti-CTLA-4 therapies can cause significant systemic immune-related adverse events.
  • Next-generation antibodies aim to improve the therapeutic window of CTLA-4 blockade.

Purpose of the Study:

  • To design and evaluate novel anti-CTLA-4 antibodies with enhanced Fc-mediated effector functions.
  • To achieve conditional tumor-restricted activation of these antibodies.
  • To improve anti-tumor efficacy while minimizing systemic toxicity.

Main Methods:

  • Engineering of anti-CTLA-4 antibodies with enhanced Fc regions.
  • Incorporation of conditional activation mechanisms for tumor targeting.
  • Preclinical testing in relevant tumor models to assess efficacy and toxicity.

Main Results:

  • Demonstrated enhanced Fc-mediated effector functions in engineered antibodies.
  • Showcased conditional tumor-restricted activation, limiting systemic exposure.
  • Observed robust anti-tumor activity in preclinical models.
  • Reported a favorable therapeutic index with reduced systemic immune-related toxicity.

Conclusions:

  • Next-generation anti-CTLA-4 antibodies offer a promising strategy for cancer immunotherapy.
  • Enhanced Fc function combined with conditional activation can improve efficacy and safety.
  • These engineered antibodies represent a potential advancement in treating various cancers.